ARVN Valuation Metrics
FCF$-275.70M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Arvinas Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC ® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Did you know?
Holds 16.1x more cash than debt — a strong balance sheet.
Current Price
$10.51
+6.16%Profile
Valuation (TTM)
Market Cap$675.00M
P/E-8.35
EV—
P/B1.56
Shares Out64.22M
P/Sales2.57
Revenue$262.60M
EV/EBITDA—
Arvinas Inc (ARVN) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →ARVN Valuation & Fair Value Analysis
Arvinas Inc (ARVN) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -8.35. Price-to-book ratio is 1.56. Price-to-sales ratio is 2.57. PEG ratio is -0.16.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Arvinas Inc's intrinsic value.